exploring endocrine therapy innovations for high-risk hormone receptor-positive breast cancer
Published 2 months ago • 72 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
6:09
adjuvant endocrine therapy for breast cancer: optimal durations and regimens
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
4:01
advances in the teatment of high-risk early-stage hormone receptor positive breast cancer
-
0:42
role of endocrine therapy in early-stage hr-positive breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
8:30
hr breast cancer: endocrine therapy, surgery and radiotherapy
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
17:31
prioritising patients for breast cancer surgery during covid-19: a surgeon's perspective
-
0:35
duration of endocrine therapy in early breast cancer
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
6:48
how to use endocrine therapy in premenopausal women with er early breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
3:12
combination treatments for premenopausal breast cancer: endocrine therapy and ovarian suppression
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
1:14
endocrine therapy resistance in er metastatic breast cancer
-
1:19
optimizing adjuvant therapy: chemotherapy necessity in hr-positive breast cancer